Table 3.
One-year clinical outcomes
| All regions n=35 389 | Europe n=24 819 | Asia n=6305 | Africa/Middle East n=2081 | South America/Mexico n=2184 | P value | |
| Target lesion failure† | 3.2% (1135/35 389) | 3.5% (867/24 819) | 2.2% (137/6305)* | 2.0% (41/2081)* | 4.1% (90/2184) | <0.0001 |
| Cardiac death† | 1.3% (455/35 389) | 1.3% (320/24 819) | 0.9% (59/6305)* | 0.9% (19/2081) | 2.6% (57/2184)* | <0.0001 |
| Target vessel MI† | 0.9% (316/35 389) | 1.1% (271/24 819) | 0.4% (22/6305)* | 0.6% (13/2081)* | 0.5% (10/2184)* | <0.0001 |
| Clinically driven TLR† | 1.7% (591/35 389) | 1.9% (458/24 819) | 1.2% (78/6305)* | 1.1% (22/2081)* | 1.5% (33/2184) | <0.0001 |
| All-cause death† | 2.1% (746/35 389) | 2.2% (539/24 819) | 1.6% (101/6305)* | 1.4% (28/2081)* | 3.6% (78/2184)* | <0.0001 |
| All MI† | 1.2% (423/35 389) | 1.5% (361/24 819) | 0.4% (25/6305)* | 1.1% (22/2081) | 0.7% (15/2184)* | <0.0001 |
| Revascularisations | ||||||
| TVR† | 2.4% (830/35 389) | 2.6% (655/24 819) | 1.6% (100/6305)* | 1.4% (28/2081)* | 2.2% (47/2184) | <0.0001 |
| TV non-TLR† | 0.7% (261/35 389) | 0.9% (226/24 819) | 0.3% (17/6305)* | 0.3% (6/2081)* | 0.6% (12/2184) | <0.0001 |
| TLR† | 1.7% (614/35 389) | 1.9% (469/24 819) | 1.4% (86/6305)* | 1.1% (23/2081)* | 1.7% (36/2184) | <0.0001 |
| Clinically driven revascularisations | ||||||
| TVR† | 2.3% (800/35 389) | 2.6% (638/24 819) | 1.4% (91/6305)* | 1.3% (27/2081)* | 2.0% (44/2184) | <0.0001 |
| TV non-TLR* | 0.7% (252/35 389) | 0.9% (218/24 819) | 0.3% (16/6305)* | 0.3% (6/2081)* | 0.6% (12/2184) | <0.0001 |
| Target vessel failure* | 3.7% (1308/35 389) | 4.1% (1016/24 819) | 2.4% (148/6305)* | 2.2% (46/2081)* | 4.5% (98/2184) | <0.0001 |
| Stent thrombosis† | ||||||
| Definite † | 0.4% (146/35 389) | 0.5% (125/24 819) | 0.1% (9/6305)* | 0.2% (4/2081)* | 0.4% (8/2184) | <0.0001 |
| Probable† | 0.3% (94/35 389) | 0.2% (60/24 819) | 0.2% (13/6305) | 0.2% (4/2081) | 0.8% (17/2184)* | <0.0001 |
| Definite/probable† | 0.7% (238/35 389) | 0.7% (183/24 819) | 0.4% (22/6305)* | 0.4% (8/2081) | 1.1% (25/2184)* | <0.0001 |
| Possible† | 0.5% (190/35 389) | 0.6% (141/24 819) | 0.4% (23/6305)* | 0.4% (8/2081) | 0.8% (18/2184) | <0.0001 |
| All bleedings | 2.9% (1013/35 389) | 3.7% (923/24 819) | 0.6% (36/6305)* | 0.7% (15/2081)* | 1.8% (39/2184)* | <0.0001 |
| BARC 2–5 bleeding | 2.1% (743/35 389) | 2.7% (675/24 819) | 0.5% (29/6305)* | 0.6% (12/2081)* | 1.2% (27/2184) | <0.0001 |
| BARC 3–5 bleeding | 0.9% (304/35 389) | 1.1% (265/24 819) | 0.2% (14/6305)* | 0.4% (8/2081)* | 0.8% (17/2184) | <0.0001 |
Events are reported as % (n) in the patient population that reached 1-year follow-up, died during follow-up or who had event that contributed to the primary outcome measure (n=35 389). The p value is given for the comparison over all 4 regions.
Target lesion failure: composite of cardiac death, TV-MI or clinically driven TLR. Target vessel failure: composite of cardiac death, TV-MI or clinically driven TVR.
*Indicates a p value <0.05 for the difference in characteristics between the region as compared with Europe.
†Events were adjudicated by an independent Clinical Event Committee.
MI, myocardial infarction; TV non-TLR, target vessel but non-target lesion revascularisation; TLR, target lesion revascularisation; TVR, target vessel revascularisation.